Nirogacestat hydrobromide - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for nirogacestat hydrobromide and what is the scope of freedom to operate?
Nirogacestat hydrobromide
is the generic ingredient in one branded drug marketed by Springworks and is included in one NDA. There are nineteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Nirogacestat hydrobromide has sixty-eight patent family members in forty-four countries.
One supplier is listed for this compound.
Summary for nirogacestat hydrobromide
International Patents: | 68 |
US Patents: | 19 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
DailyMed Link: | nirogacestat hydrobromide at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for nirogacestat hydrobromide
Generic Entry Date for nirogacestat hydrobromide*:
Constraining patent/regulatory exclusivity:
FOR ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS WHO REQUIRE SYSTEMIC TREATMENT Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for nirogacestat hydrobromide
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for nirogacestat hydrobromide
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 1730119 | COMPOSES D'IMIDAZOLE DESTINES AU TRAITEMENT DE TROUBLES NEURODEGENERATIFS (IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS) | ⤷ Try a Trial |
Norway | 338263 | ⤷ Try a Trial | |
Ukraine | 83899 | СОЕДИНЕНИЯ ИМИДАЗОЛА ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ РАССТРОЙСТВ;СПОЛУКИ ІМІДАЗОЛУ ДЛЯ ЛІКУВАННЯ НЕЙРОДЕГЕНЕРАТИВНИХ РОЗЛАДІВ (IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS) | ⤷ Try a Trial |
Japan | 2022553479 | (S)-2-(((S)-6,8-ジフルオロ-1,2,3,4-テトラヒドロナフタレン-2-イル)アミノ)-N-(1-(2-メチル-1-(ネオペンチルアミノ)プロパン-2-イル)-1H-イミダゾール-4-イル)ペンタンアミドの固体状態形態およびその使用 | ⤷ Try a Trial |
European Patent Office | 4010322 | FORMES À L'ÉTAT SOLIDE DE (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TÉTRAHYDRONAPHTHALÉN-2-YL)AMINO)-N-(1-(2-MÉTHYL-1-(NÉOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE ET UTILISATIONS ASSOSIÉES (SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |